Nuvilex (PMCB) Stock Price, News & Analysis

Company Overview

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Key Stats

• Today's Range: $0.51 to $0.54
• 50-Day Range: $0.52 to $0.83
• 52-Week Range: $0.50 to $1.51
• Volume: 54,829 shs
• Average Volume: 136,937 shs
• Market Capitalization: $5.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nuvilex Stock Analysis - MarketRank™

Nuvilex scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Nuvilex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nuvilex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvilex is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvilex is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvilex has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.05% of the float of Nuvilex has been sold short.

Short Interest Ratio / Days to Cover

Nuvilex has a short interest ratio ("days to cover") of 1.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuvilex has recently decreased by 9.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvilex does not currently pay a dividend.

Dividend Growth

Nuvilex does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for PMCB on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuvilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.98% of the stock of Nuvilex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

34.24% of the stock of Nuvilex is held by institutions.

Company Calendar

• Last Earnings: 12/18/2025
• Today: 8/20/2026
• Next Earnings (Estimated): 8/24/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PMCB
• CIK: 1157075
• Web: pharmacyte.com
• Phone: 917-595-2850
• Fax: 917-595-2851
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 0.25%
• Return on Assets: 0.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 45.30
• Quick Ratio: 45.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 10,740,000
• Free Float: 9,557,000
• Market Cap: $5.72 million
• Optionable: Optionable
• Beta: 0.57